Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Equity Investments Gains from Equity Investments Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Cresco Labs (CRLBF) Short-Term Debt issuances (2025 - 2026)

Cresco Labs filings provide 2 years of Short-Term Debt issuances readings, the most recent being $10.9 million for Q1 2026.

On a quarterly basis, Short-Term Debt issuances changed N/A to $10.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.9 million, a N/A change, with the full-year FY2025 number at $10.8 million, changed N/A from a year prior.
Short-Term Debt issuances hit $10.9 million in Q1 2026 for Cresco Labs, up from $10.8 million in the prior quarter.
In the past five years, Short-Term Debt issuances ranged from a high of $10.9 million in Q1 2026 to a low of $10.8 million in Q4 2025.